These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 32893246)

  • 1. [Novel migraine treatment with CGRP-related monoclonal antibodies].
    Shibata M
    Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of CGRP-Related Monoclonal Antibodies in Migraine Management].
    Shibata M
    Brain Nerve; 2021 Apr; 73(4):327-337. PubMed ID: 33824220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin gene-related peptide (CGRP): a new target for migraine.
    Russo AF
    Annu Rev Pharmacol Toxicol; 2015; 55():533-52. PubMed ID: 25340934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
    Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
    BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CGRP in Migraine.
    Edvinsson L
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.
    Edvinsson L
    J Intern Med; 2022 Oct; 292(4):575-586. PubMed ID: 35532284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
    Cohen F; Yuan H; Silberstein SD
    BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug.
    Naduchamy KP; Parthasarathy V
    Curr Mol Pharmacol; 2021; 14(1):11-26. PubMed ID: 32838728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP and migraine: from bench to bedside.
    Edvinsson L
    Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
    Suzuki K; Suzuki S; Fujita H; Sakuramoto H; Shioda M; Hirata K
    Neuropsychopharmacol Rep; 2024 Jun; 44(2):482-484. PubMed ID: 38602109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.
    Szperka CL; VanderPluym J; Orr SL; Oakley CB; Qubty W; Patniyot I; Lagman-Bartolome AM; Morris C; Gautreaux J; Victorio MC; Hagler S; Narula S; Candee MS; Cleves-Bayon C; Rao R; Fryer RH; Bicknese AR; Yonker M; Hershey AD; Powers SW; Goadsby PJ; Gelfand AA
    Headache; 2018 Nov; 58(10):1658-1669. PubMed ID: 30324723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.